Compare Coursera Inc (COUR) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Citius Pharmaceuticals Inc — how do they compare? Coursera Inc trades at $5.28 (market cap $1.39B), while Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M). The key difference: Coursera Inc is far larger — about 102.1× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 9,728,980). Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Citius Pharmaceuticals Inc for 16 Days on average.
| COUR | CTXR | |
|---|---|---|
Market Cap | $1.39B | $13.62M |
Volume | 9,728,980 | 132,438 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $1.82 |
52-Week Low | $4.64 | $0.48 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | $648.49M | $3.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% on the day, with a bearish technical signal and neutral oscillators. Revenue has grown from $524M in 2022 to $757.5M in 2025, but the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights AI platform developments and significant institutional buying interest.
The stock offers potential upside to the $7.40 analyst consensus target but faces risks from persistent losses and competitive pressures. Positive cash flow and subscriber growth are key strengths, yet profitability challenges and integration costs from recent acquisitions present headwinds for near-term performance.
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
